NEW YORK, April 27, 2015 /PRNewswire/ -- OTC Markets
Group Inc. (OTCQX: OTCM), operator of Open, Transparent and
Connected financial marketplaces, today announced Immunovaccine
Inc. (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine development
company, has qualified to trade on the OTCQX® Best Marketplace.
Logo -
http://photos.prnewswire.com/prnh/20110118/MM31963LOGO
Immunovaccine begins trading today on OTCQX under the symbol
"IMMVF." U.S. investors can find current financial disclosure
and Real-Time Level 2 quotes for the company on
www.otcmarkets.com.
"We are pleased to welcome Immunovaccine to the family of
investor-friendly U.S. and international companies on OTCQX," said
R. Cromwell Coulson, President and
CEO of OTC Markets Group. "Trading on OTCQX will provide
Immunovaccine's U.S. shareholders transparent trading and
convenient access to the company's news and financial disclosure so
they can more easily analyze, value and trade its
securities. We look forward to supporting Immunovaccine in its
continued growth and success in the public markets."
"The OTCQX offers U.S. investors easier access to Immunovaccine
as we expand our presence in the rapidly evolving field of cancer
immunotherapy," said Marc Mansour,
CEO of Immunovaccine. "Trading on the OTCQX enables us to introduce
the company to a broader range of investors and retail brokers in
the U.S., at a time when our sector has emerged as one of the most
promising in cancer therapy."
Dorsey & Whitney LLP serves as Immunovaccine's Principal
American Liaison ("PAL") on OTCQX, responsible for providing
professional guidance on OTCQX requirements and U.S. securities
laws.
Immunovaccine Inc. develops cancer immunotherapies and
infectious disease vaccines based on the company's DepoVax
platform, a patented formulation that provides controlled and
prolonged exposure of antigens and adjuvant to the immune
system. Immunovaccine has advanced two T cell activation
therapies for cancer through Phase 1 human clinical trials and is
currently conducting a Phase 2 study with its lead cancer vaccine
therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is
expected to enter additional Phase 2 clinical studies in ovarian
cancer and glioblastoma (brain cancer). The company is also
advancing an infectious disease pipeline including innovative
vaccines for respiratory syncytial virus (RSV) and anthrax.
About OTC Markets Group Inc.
OTC Markets Group
Inc. (OTCQX: OTCM) operates Open, Transparent and Connected
financial marketplaces for 10,000 U.S. and global
securities. Through our OTC Link® ATS, we directly link a
diverse network of broker-dealers that provide liquidity and
execution services for a wide spectrum of securities. We
organize these securities into marketplaces to inform investors of
opportunities and risks: the OTCQX® Best Marketplace; the OTCQB®
Venture Marketplace; and the OTC Pink® Open Marketplace. Our
data-driven platform enables investors to easily trade through the
broker of their choice at the best possible price and empowers a
broad range of companies to improve the quality and availability of
information for their investors. To learn more about how we create
better informed and more efficient financial marketplaces, visit
www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and
SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
Saskia
Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428,
saskia@otcmarkets.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-immunovaccine-to-otcqx-300072084.html
SOURCE OTC Markets Group Inc.